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Abstract 39 
Missense mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) cause the majority of familial 40 
and some sporadic forms of Parkinsons disease (PD). The hyperactivity of LRRK2 kinase 41 
induced by the pathogenic mutations underlies neurotoxicity, promoting the development of 42 
LRRK2 kinase inhibitors as therapeutics. Many potent and specific small molecule LRRK2 43 
inhibitors have been reported with promise. However, nearly all inhibitors are ATP competitive 44 
 some with unwanted side effects and unclear clinical outcome - alternative types of LRRK2 45 
inhibitors are lacking. Herein we find 5-deoxyadenosylcobalamin (AdoCbl), a physiological 46 
form of the essential micronutrient vitamin B12 as a mixed-type allosteric inhibitor of LRRK2 47 
kinase activity. Multiple assays show that AdoCbl directly binds LRRK2, leading to the 48 
alterations of protein conformation and ATP binding in LRRK2. STD-NMR analysis of a 49 
LRRK2 homologous kinase reveals the contact sites in AdoCbl that interface with the kinase 50 
domain. Furthermore, we provide evidence that AdoCbl modulates LRRK2 activity through 51 
disruption of LRRK2 dimerization. Treatment with AdoCbl inhibits LRRK2 kinase activity in 52 
cultured cells and brain tissue, and importantly prevents neurotoxicity in primary rodent cultures 53 
as well as in transgenic C. elegans and D. melanogaster expressing LRRK2 disease variants. 54 
Finally, AdoCbl alleviates deficits in dopamine release sustainability caused by LRRK2 disease 55 
variants in mouse models. Our study uncovers vitamin B12 as a novel class of LRRK2 kinase 56 
modulator with a distinct mechanism, which can be harnessed to develop new LRRK2-based PD 57 
therapeutics in the future.  58 
 59 
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Introduction 61 
Parkinsons disease (PD) is the most common chronic neurodegenerative movement 62 
disorder affecting 1% of the world population over the age of sixty. The pathological hallmarks 63 
of PD include the age-dependent loss of dopaminergic neurons in the substantia nigra and the 64 
progressive spatiotemporal distribution of Lewy bodies and Lewy neurites1. There is currently no 65 
cure or disease-modifying therapy for PD, and available treatments target only the symptoms of 66 
the disease but not its progression2. In addition, the pathogenesis of PD remains poorly 67 
understood. Discovered over a decade ago, Leucine-Rich Repeat Kinase 2 (LRRK2) has now 68 
emerged as a major target not only for understanding the molecular basis of PD pathogenesis but 69 
also for therapeutic intervention3. 70 
 Missense mutations in the PARK8/LRRK2 gene represent the prevalent cause for 71 
autosomal-dominant PD4,5. In addition, LRRK2 mutations have been implicated in a significant 72 
number of sporadic PD cases6-9. PD-linked LRRK2 variants associate with neuropathologies and 73 
clinical symptoms indistinguishable from idiopathic PD cases10,11, suggesting that both inherited 74 
and sporadic forms of the disease share a similar pathogenic mechanism. LRRK2 encodes a 75 
286kDa protein containing catalytic GTPase and kinase domains, as well as Armadillo, Ankyrin, 76 
LRR and WD40 protein-protein interaction accessory domains (Fig. 1a). LRRK2 adopts a highly 77 
compact dimer structure with extensive intramolecular interactions12, and dimerization has been 78 
proposed to correlate with LRRK2 kinase activity in vitro13. Of the six reported pathogenic 79 
mutations, the G2019S variant has the highest prevalence14, accounting for 1% of sporadic and 80 
5% of hereditary PD cases worldwide10, and up to 3040% of all PD cases among North 81 
Africans and Ashkenazi Jews15. Located in a conserved region of the kinase activation loop, the 82 
G2019S variant has been consistently associated with increased LRRK2 kinase activity in 83 
 4
vitro
13,16-18
 and in vivo19-22. In addition, the G2019S variant also increases the phosphorylation of 84 
a subset of Rab GTPases, recently identified as promising physiological LRRK2 substrates23,24.  85 
 Multiple lines of evidence demonstrate that LRRK2 kinase hyperactivity caused by PD 86 
pathogenic mutations, including G2019S, is causal to neurotoxicity or neuronal dysfunctions. 87 
LRRK2 kinase inhibitors attenuate the cell toxicity caused by the G2019S mutation in primary 88 
cortical neurons25 and normalize G2019S-mediated postsynaptic abnormal activity in brain slice 89 
cultures26. In addition, LRRK2 kinase activity inhibitors prevent G2019S-potentiated α-90 
synuclein accumulation in dopaminergic neurons27,28, and their administration suppressed 91 
neurodegeneration in C. elegans, D. melanogaster and mouse PD models25,29-31. Consequently, 92 
extensive effort has been devoted to the development of ATP-competitive small molecule 93 
LRRK2 kinase inhibitors. Early generation kinase inhibitors displayed high potency against 94 
LRRK2, but lacked the specificity required to be considered for therapeutics25,32-34. Among the 95 
next generation, several inhibitors were highly potent and specific, but did not possess the 96 
pharmacokinetic properties for effective brain penetration35,36, while others elicited dose toxicity 97 
and abnormal lung phenotypes in nonhuman primates37. The current generation of ATP-98 
competitive inhibitors show promise, but will require further modification38 and preclinical 99 
testing39 before their therapeutic potential can be fully assessed. Remarkably, LRRK2 kinase 100 
activity inhibitors displaying alternative mechanisms of inhibition to these ATP-competitive 101 
inhibitors have yet to be reported.  102 
Here we discovered that the FDA-approved natural compound 5-103 
deoxyadenosylcobalamin (AdoCbl), one of two physiological forms of the essential human 104 
micronutrient vitamin B12, is a unique mixed-type allosteric modulator of LRRK2 kinase 105 
activity. AdoCbl is capable of disturbing LRRK2 protein conformation and dimerization. In 106 
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addition, we explore the ability of AdoCbl to prevent mutant LRRK2 induced neurotoxicity and 107 
Parkinson-like phenotypes in PD animal models. We conclude that vitamin B12 is a novel type of 108 
LRRK2 kinase modulator, which is distinguished from other ATP competitive inhibitors. Future 109 
experiment should investigate the structural basis for LRRK2- vitamin B12 interaction that can be 110 
harnessed to develop new therapeutics for LRRK2-based PD. 111 
 112 
Results 113 
Identification of vitamin B12 as a LRRK2 kinase activity inhibitor 114 
AdoCbl (Supplimentary information, Fig. S1a) was identified as a kinase activity inhibitor of 115 
FLAG-tagged wild type (WT) LRRK2 purified from BAC transgenic mouse brain19 116 
(Supplimentary information, Fig. S1b) from a high-throughput screen (HTS) of a small library of 117 
2,080 FDA-approved compounds (Supplimentary information, Table S1). To assay LRRK2 118 
kinase activity we measured the time-resolved fluorescence resonance energy transfer (TR-119 
FRET) between phosphorylated Fluorescein-LRRKtide peptide and Terbidium-labeled anti-120 
pLRRKtide antibody40. In this screen AdoCbl displayed a half-maximal inhibitory concentration 121 
(IC50) of 1.2 µM (Fig. 1b). Vitamin B12 consists of a central cobalt ion that is equatorially 122 
chelated by a tetradentate corrin macrocycle and up to two axially coordinating ligands 123 
(Supplimentary information, Fig. S1a). The lower (α)-coordinating ligand is usually a 124 
dimethylbenzimidazole (DMZ) base that connects to the f-side chain of the chelator by an α-125 
ribazole containing backbone41.  126 
Vitamin B12 has additional forms in addition to AdoCbl, including cyanocobalamin 127 
(CNCbl), hydroxycobalamin (HOCbl), and methylcobalamin (MeCbl), which are distinguished 128 
by their (β)-coordinating ligand42 (Supplimentary information, Fig. S1a). Only MeCbl and 129 
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AdoCbl are physiologically active in cells, as coenzymes of MeCbl-dependent methionine 130 
synthase and AdoCbl-dependent methylmalonyl coenzyme A mutase42. In humans, these 131 
enzymatic reactions play a key role in the metabolism of amino acids, nucleotides, and fatty 132 
acids, in addition to the normal functioning of the nervous system, and the formation of red 133 
blood cells43.  134 
Similar to AdoCbl, these other forms of vitamin B12 inhibited the LRRK2 catalyzed 135 
phosphorylation of the LRRKtide peptide with an IC50 of ~1 µM (Fig. 1b), suggesting that the 136 
nature of the (β)-coordinating ligand was not essential for the inhibition. Next, we validated the 137 
LRRK2 kinase inhibition by the various forms of vitamin B12 using highly pure strep-tagged 138 
LRRK2-WT expressed in HEK293 cells (Supplimentary information, Fig. S1c). To this end, we 139 
assayed LRRK2 autophosphorylation (Fig. 1c) and phosphorylation of the generic substrate 140 
myelin basic protein (MBP) (Fig. 1d) by measuring the incorporation of radioactive 32P. In both 141 
cases, we determined IC50s in the ~10 µM range for each form of vitamin B12. We note that 142 
AdoCbl inhibited LRRK2-G2019S catalyzed phosphorylation of the recently identified LRRK2 143 
physiological substrate Rab1023,24 also with a ~10 µM IC50 (Fig. 1e).  144 
Next, we derived Mouse Embryonic Fibroblast (MEF) cells from our LRRK2-G2019S 145 
BAC transgenic mice19, and incubated them with AdoCbl, CNCbl, HOCbl, or MeCbl to measure 146 
their effect on LRRK2 autophosphorylation. As a readout we measured autophosphorylation 147 
using anti-LRRK2 pS93544 and pS129220 antibodies. In this system both antibodies reported 148 
decreased LRRK2 autophosphorylation levels upon treatment with the established LRRK2 GNE-149 
102320 inhibitor (Supplimentary information, Figs. S2a-b). These MEFs constitutively 150 
overexpress the pathogenic LRRK2-G2019S variant, which in accordance with literature 151 
displayed kinase hyperactivity compared to LRRK2-WT19-22 (Supplimentary information, Fig. 152 
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S2c). Interestingly, we found that only AdoCbl, but not the other forms of vitamin B12, exhibited 153 
inhibition of LRRK2-G2019S autophosphorylation in MEF cells with an IC50 of ~10 µM, similar 154 
to that measured in vitro (Figs. 1f-g). We observed a similar inhibition profile for the different 155 
forms of vitamin B12 in macrophages derived from the LRRK2-G2019S transgenic mice 156 
(Supplimentary information, Fig. S2d). The lack of inhibition displayed by CNCbl, HOCbl, or 157 
MeCbl is not understood at present, but one possibility is that differences in cellular uptake, 158 
localization and metabolism in the cells affect their efficacy compared to AdoCbl. Because 159 
AdoCbl showed the greatest potential for LRRK2 inhibition in cultured cells we focused our 160 
research efforts on this physiological form of vitamin B12. 161 
 162 
AdoCbl binds directly to LRRK2 163 
We next tested if AdoCbl binds directly to human LRRK2. We first used agarose functionalized 164 
with AdoCbl to pull-down purified LRRK2, which could be eluted as a function of AdoCbl 165 
concentration (Fig. 2a and Supplimentary information, Fig. S3). In thermal shift assays 166 
(TSA)45 the melting temperature of LRRK2 increased substantially from 50 to 54°C in the 167 
presence of AdoCbl (Fig. 2b). This thermostabilization by AdoCbl was comparable to that 168 
measured in the presence of the established LRRK2 kinase inhibitor PF-0644747538. 169 
Furthermore, we applied microscale thermophoresis (MST)46 to measure the binding affinity of 170 
AdoCbl for LRRK2 and determined an apparent dissociation equilibrium constant (KD) of 12.0 171 
and 4.1 ȝM for purified LRRK2-WT and LRRK2-G2019S, respectively (Fig. 2c), in agreement 172 
with our IC50 values. As a validation of the MST assay, under the same conditions LRRK2-173 
G2019S binds PF-06447475 with a KD of 70 nM (Fig. 2d), in line with the reported IC50 of 11 174 
nM for this inhibitor38.  175 
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 We next sought to identify the functional groups in AdoCbl responsible for interacting 176 
with LRRK2 by using an extension of the saturation transfer difference (STD) NMR method 177 
termed ATP-STD NMR47. This method was developed to screen protein kinase inhibitors by 178 
recording STD signals in the presence of competing ATP48. Due to an unstable and aggregation 179 
prone human LRRK2 kinase domain, which makes it intractable for biophysical/structural 180 
analysis, we decided to use the humanized kinase domain of the Roco4 protein from 181 
Dictyostelium discoideum
49. The kinase domain of Roco4 (amino acids 10181292) has a 47% 182 
similarity with the kinase domain of human LRRK2 (amino acids 18792138), and its 183 
humanized variant, where amino acid residues F1107 and F1161 are substituted for Leucine to 184 
mimic the residues L1949 and L2001 in LRRK2, is considered a valuable model for the 185 
structural characterization of LRRK2 kinase inhibitors47,49. We first verified that AdoCbl 186 
inhibited autophosphorylation of the humanized Roco4 kinase (Fig. 2e) with an IC50 of 73.6 µM 187 
(Fig. 2f). In agreement with published data47, we obtained a clear STD signal for ATP binding to 188 
Roco4 kinase (Fig. 2g, orange spectrum). Addition of AdoCbl to the ATP/Roco4 sample in a 189 
1:1 AdoCbl:ATP ratio resulted in the emergence of additional STD signals corresponding to 190 
AdoCbl protons, confirming a direct binding of AdoCbl to Roco4. At a 10:1 AdoCbl:ATP ratio, 191 
the STD peaks corresponding to AdoCbl became much stronger while ATP peaks weakened, 192 
demonstrating that AdoCbl diminished ATP binding to Roco4 kinase. Stronger STD signals 193 
likely correspond to AdoCbl protons in the vicinity or at the protein binding interface. These 194 
protons are distributed around one side of the molecule and are contributed by the adenine, 195 
corrin, and DMZ moieties (Fig. 2h). 196 
 197 
AdoCbl is a mixed-type allosteric LRRK2 kinase inhibitor 198 
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The current collection of commercially available LRRK2 kinase inhibitors, including the latest 199 
generation PF-0644747538 and MLi-239, are considered to be ATP-competitive, with the 200 
exception of FX2149 that is GTP-competitive50. To determine the mode of inhibition of vitamin 201 
B12 we measured Vmax and Km as a function of ATP and in the presence of an increasing 202 
concentration of AdoCbl. For our in vitro inhibition kinetics assays we used purified full-length 203 
LRRK2-WT and LRRK2-G2019S to measure relative velocity based on the quantification of 204 
LRRK2 autophosphorylation pS1292 signal (Supplimentary information, Fig. S4). Consistent 205 
with literature13,16-18, the relative velocity of LRRK2-G2019S was two-fold higher than LRRK2-206 
WT (Supplimentary information, Table S2). Titration of AdoCbl caused a decrease in apparent 207 
Vmax and an increase in apparent Km (Figs. 3a-c), suggesting mixed-type inhibition, as confirmed 208 
by reciprocal Lineweaver-Burk plots of the data (Figs. 3b-d and Supplementary information, 209 
Table S2). Mixed-type inhibitors generally bind to an allosteric site and can affect an enzymes 210 
ability to catalyze a reaction and to bind its substrate51. To further characterize the mode of 211 
AdoCbl inhibition of LRRK2 we measured the competition with AMP-PNP using MST (Fig. 212 
3e). Under our assay conditions AMP-PNP displayed a KD of 0.9 ȝM against LRRK2 (Fig. 3f). 213 
In further support of the mixed-inhibition mode of action, increasing concentrations of AMP-214 
PNP reduced but did not overcome the binding of AdoCbl to LRRK2 (Fig. 3e).  215 
 We further compared AdoCbl with the reported ATP-competitive LRRK2 inhibitor IN-1 216 
(LRRK2-IN-1) for its ability to inhibit the human LRRK2 A2016T variant. The A2016T 217 
substitution in the ATP-site of LRRK2 results in a normally active enzyme, which is, however, 218 
significantly less sensitive to the ATP-competitive inhibitors H-1152 and sunitinib52, and up to 219 
400-fold less sensitive against LRRK2-IN-1 compared to the WT protein35. Using the G2019S 220 
mutation as a background we confirmed that the A2016T substitution confers resistance to 221 
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LRRK2-IN-1 (Supplimentary information, Figs. S5a-b). In contrast, this variant displayed a 222 
similar level of inhibition by AdoCbl as the G2019S protein alone. Similarly WT Roco4 from D. 223 
discoideum
47,49, which has a 241-fold lower affinity for LRRK2-IN-1 than humanized Roco447, 224 
was inhibited by the same degree as the humanized version (Supplimentary information, Figs. 225 
S5c-d). The data suggests distinct mechanisms of LRRK2 binding between LRRK2-IN-1 and 226 
AdoCbl.  227 
 228 
AdoCbl induces conformational changes and disrupts dimerization of LRRK2 229 
Allosteric inhibitor binding normally induces a conformational change in the enzyme that results 230 
in reduced affinity for the substrate53. To test the possibility of an AdoCbl-induced 231 
conformational change in LRRK2 we conducted limited proteolysis assays in the presence of 232 
AdoCbl. The addition of AdoCbl markedly increased the susceptibility of LRRK2 to proteolysis 233 
by both trypsin and chymotrypsin (Fig. 4a). At a 90-min. interval, we showed that the presence 234 
of AdoCbl significantly increases the sensitivity of trypsin degradation of LRRK2 protein in a 235 
dose dependent manner (Fig. 4b). This observation does not result from an enhancement of the 236 
intrinsic activity of these proteases, as demonstrated by the fact that AdoCbl did not affect the 237 
proteolysis rate of a control kinase TBK1 (Supplimentary information, Fig. S6a). Of note, the 238 
well-known ATP-competitive LRRK2 kinase inhibitors GSK2578215A36, GNE-102320 and PF-239 
0644747538, produced the opposite effect as AdoCbl, i.e. they protected LRRK2 from proteolytic 240 
digestion (Fig. 4b), whereas AMP-PNP had no effect (Supplimentary information, Fig. S6b). 241 
For more evidence in support of conformational changes in LRRK2 upon binding to AdoCbl we 242 
measured the intrinsic fluorescence of LRRK2 as a function of AdoCbl. With 27 tryptophan 243 
amino acid residues, the fluorescence emission spectra of LRRK2 at an excitation wavelength of 244 
295 nm displayed an AdoCbl dose-dependent decrease in fluorescence intensity (Fig. 4c). Note 245 
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that AdoCbl absorbs light at 295 nm and 340-360 nm, thus it was necessary to correct for the 246 
inner-filter effect (Supplimentary information, Figs. S6c-d). Such a decrease in fluorescence 247 
intensity is consistent with conformational changes in LRRK2 where initially buried tryptophan 248 
residues become exposed to the solvent as a function of AdoCbl.  249 
We hypothesize that the effect of AdoCbl binding in LRRK2 conformation alters 250 
oligomeric state of LRRK2. Ample evidence now supports dimeric LRRK2 as the main 251 
oligomeric species of the enzyme in vitro12, and available data indicates that LRRK2 252 
dimerization correlates with kinase activity13. We quantified cellular LRRK2 dimers using a 253 
novel adaptation of the proximity biotinylation approach. We expressed recombinant LRRK2 254 
protein fusion to BirA (biotin ligase) or to AP (acceptor peptide) in HEK293T cells in the 255 
presence of vehicle or AdoCbl. As a negative control BirA- and AP-LRRK2 expressing cells 256 
were lysed without having been given the biotin pulse; and in such samples, the number of 257 
labeled LRRK2 dimers purified on streptavidin plates is negligible (Fig. 4d). Expression levels 258 
of both forms of LRRK2 are comparable as determined by ELISA or Western immunoblot. Cells 259 
co-expressing BirA-LRRK2/AP-LRRK2 contain robust levels of biotinylated LRRK2 dimers, 260 
normalized to total expression of LRRK2. However, in cells treated with AdoCbl, we detected a 261 
dose-dependent reduction in the levels of LRRK2 dimers, both in cells expressing WT LRRK2, 262 
as well as in cells expressing the LRRK2-G2019S or LRRK2-I2020T variant proteins (Fig. 4e). 263 
In contrast to other LRRK2 kinase inhibitors54-56, we did not observe a significant decrease in 264 
LRRK2 expression following treatment with AdoCbl (Figs. 4d-f), indicating that this compound 265 
disrupts LRRK2 dimers without affecting expression.  266 
  267 
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AdoCbl protects dopaminergic neurons from LRRK2-G2019S induced neurotoxicity in C. 268 
elegans  269 
The degeneration of dopaminergic (DAergic) neurons is the pathological hallmark of PD2. 270 
However, recapitulating this phenotype in mammalian models of LRRK2-linked PD has been a 271 
challenge, nearly all reported genetic models (either transgenic overexpression or knock-in) 272 
failed to display clear neurodegeneration19,57-59. In contrast, invertebrate PD models of LRRK2 273 
show a robust degeneration of DAergic neurons60-63. The DAergic pathway in C. elegans is 274 
important for the basal slowing response, a behavior by which worms slow their locomotive 275 
movement when encountering food64. Transgenic LRRK2-G2019S nematodes exhibit progressive 276 
impairment of the basal slowing response, but this locomotive behavioral deficit can be restored 277 
by treatment with the LRRK2 kinase inhibitors LRRK2-IN-1 and TTT-300230. In this C. elegans 278 
model of LRRK2 PD, these two inhibitors targeted specifically LRRK2, as they were ineffective 279 
against the neurodegenerative phenotype displayed in transgenic LRRK2-A2016T/G2019S worms 280 
carrying the inhibitor-resistant LRRK2 A2016T mutation30. Therefore, we selected the 281 
established human LRRK2-G2019S C. elegans model to ask if AdoCbl protects against DAergic 282 
neuron degeneration. LRRK2-G2019S transgenic worms that were fed up to 1.25 µM AdoCbl 283 
during their larval stage resisted the locomotive behavioral deficit on adult day 3 in a dose-284 
dependent manner with a half-maximal effective concentration (EC50) value of 0.53 µM (Fig. 285 
5a). Consistent with the lack of an effect of the LRRK2 A2016T mutation on the inhibition by 286 
AdoCbl in vitro (Supplimentary information, Figs. S5a-b), treating transgenic LRRK2-287 
A2016T/G2019S worms with AdoCbl resulted in a rescued neurodegenerative phenotype 288 
(Supplimentary information, Fig. S7a). The data also supports the distinct mechanism of AdoCbl 289 
in blocking LRRK2 activity and LRRK2 associated neurodegeneration from IN-1. Additionally, 290 
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the AdoCbl-induced rescue was observed in transgenic LRRK2-R1441C worms as well, which 291 
also display an impaired basal slowing response (Supplimentary information, Fig. S7b). C. 292 
elegans possess eight DAergic neurons that can be readily visualized by coupling GFP to a DA-293 
neuron-specific promoter. Four GFP-tagged DAergic neurons of cephalic sensilla (CEP neurons) 294 
in the head were examined using fluorescence microscopy. Overexpression of LRRK2-G2019S 295 
causes age-dependent degeneration of these DAergic neurons, where less than 60% remain on 296 
adult day 9, compared to 75% in control worms expressing GFP alone. When fed 1.25 µM 297 
AdoCbl during their larval stage, age-synchronized adult LRRK2-G2019S worms displayed a 298 
robust increase in DAergic neuron survival, nearly back to the levels of the GFP-control worms 299 
(Figs. 5b-c). As in the case of TTT-3002 and LRRK2-IN-130, treatment of WT worms 300 
expressing GFP marker alone with AdoCbl did not result in any significant changes in basal 301 
slowing response or DAergic neuron survival, suggesting that the effect of AdoCbl was specific 302 
to the transgenic LRRK2-G2019S worms.  303 
 304 
AdoCbl prevents LRRK2-G2019S induced neurotoxicity in D. melanogaster model of PD 305 
Signal regulation in the human retina depends largely on dopamine65, and this process can be 306 
affected by the loss of DA that is characteristic in PD patients66. In D. melanogaster, vision is 307 
also regulated by comparable DAergic circuits67,68. Transgenic overexpression of the human 308 
LRRK2-G2019S gene in D. melanogaster has been shown to elicit DA-dependent retinal 309 
degeneration and loss of visual response due to an abnormal increase in contrast sensitivity, 310 
which can be rescued using LRRK2 kinase activity inhibitors31,69. After feeding Drosophila 311 
larvae with AdoCbl at concentrations up to 2.5 µM, we recorded the visual response to flickering 312 
blue light in 1-day-old flies. Our Fast Fourier Transform (FFT) algorithm separates this visual 313 
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response according to the first three stages of the fly visual system: photoreceptors, lamina 314 
neurons, and medulla neurons (Fig. 6a). Increasing the contrast of the flickering light resulted in 315 
a greater retinal response of the fly, revealing characteristic Contrast Response Functions (CRFs) 316 
that are dependent on the combination of genotype and AdoCbl treatment (Fig. 6b). In the 317 
photoreceptors and lamina neurons, the physiological response increased and plateaued at 70% 318 
applied contrast, while the medulla neurons generated a complex response, as indicated by the 319 
peak response at 40% applied contrast. In each case, flies with dopaminergic expression of 320 
LRRK2-G2019S have a much greater response compared to those expressing LRRK-WT. 321 
Notably, feeding flies with 2.5 µM AdoCbl throughout larval life rescued the LRRK2-G2019S 322 
phenotype completely, with the photoreceptor, lamina neurons and medulla neurons all showing 323 
a CRF close to that of WT flies (Fig. 6b). Furthermore, titration of AdoCbl revealed an EC50 324 
between 250 and 500 nM in all three stages of the visual pathway (Fig. 6c, and Supplimentary 325 
information, Fig. S8). To determine the specificity of AdoCbl toward LRRK2 kinase activity, 326 
we tested a 2.5 µM concentration against flies with a kinase-dead background (LRRK2-G2019S-327 
K1906M) and found no significant change in any of the three measured regions (Fig. 6d). In 328 
contrast to the results from C. elegans, treating wild-type drosophila with a 2.5 µM 329 
concentration of AdoCbl significantly rescues the visual response (Fig. 6e). Finally, we tested for 330 
off-target effects by feeding 2.5 µM of AdoCbl to flies with little expression of the LRRK2 331 
homolog (dLRRK¯) and found no statistically significant difference between any of the 332 
photoreceptor, lamina and medulla neurons (Fig. 6f).  333 
 334 
AdoCbl prevents LRRK2-G2019S induced neurotoxicity and rescues deficits in dopamine 335 
transmission in LRRK2-PD mouse models  336 
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 Previous studies have demonstrated that transient overexpression of LRRK2-G2019S, but 337 
not LRRK2-WT, leads to toxicity in primary cortical neuron cultures70,71. We employed the same 338 
approach and found that transfection of LRRK2-G2019S indeed caused neurotoxicity in 339 
dissociated cortical neurons, as evidenced by apoptotic nuclear features. Treatment of the 340 
transfected neurons with AdoCbl, however, suppressed the frequency of apoptotic neurons in a 341 
dose-dependent manner (Fig. 7a). As a positive control in this assay, the most recent generation 342 
LRRK2 inhibitor MLi-239 showed potent protection at a 10 nM concentration.  343 
 The lack of frank neurodegeneration in nearly all LRRK2 transgenic mouse models 344 
prevents us from testing AdoCbl neuroprotection in vivo. However, a common pathological 345 
feature for reported LRRK2 models is the deficit in DA transmission19,72. To investigate if 346 
AdoCbl prevents such a defect, we first tested the inhibition of neuronal LRRK2 by AdoCbl 347 
using striatal brain slices from LRRK2-G2019S BAC transgenic mice under ex vivo conditions. 348 
Striatal slices were incubated in oxygenated artificial cerebrospinal fluid (ACSF) for two hours 349 
in the presence of LRRK2 inhibitor or vehicle. Administration of AdoCbl in the ACSF caused 350 
dose-dependent inhibition of LRRK2 autophosphorylation in slice lysates (Fig. 7b). Similarly, 351 
GNE-1023 exhibited dose dependent inhibition of LRRK2 under the same conditions (SI 352 
Supplimentary information, Figs. S9a-b). Compared to WT controls, LRRK2-G2019S BAC 353 
transgenic mice were reported to have decreased sustainability of evoked DA release at the age 354 
of 12 months old19. Therefore, we measured single-pulse evoked DA release sustainability in 355 
striatal slices from LRRK2-G2019S BAC transgenic mice and WT littermates at the age of 12-15 356 
months using Fast Scan Cyclic Voltammetry (FSCV)73(Figs. 7c-d). A bipolar stimulating 357 
electrode was placed in the dorsal striatum ~150 µm from the recording microelectrode and 358 
depolarizing currents were applied at 2-minute intervals for 20 minutes. In control slices, the 359 
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amplitude of DA release at a given site evoked by single pulses decreased with the first few 360 
stimulations and declined by 20% by the end of the 20-minute period. Consistent with a previous 361 
report19, this decline was much more profound in the brain slices of the G2019S mice. 362 
Remarkably, AdoCbl alleviated this deficit and restored the sustainability to the level of WT 363 
control slices.  364 
In addition, we examined the effects of AdoCbl using striatal slices from another preclinical 365 
LRRK2-R1441G BAC transgenic mouse model. The declined DA release evoked by 2-minute 366 
intervals during a 20-minute period was robust in slices from LRRK2-R1441G mice compared to 367 
WT controls, and again, AdoCbl alleviated this deficit, restoring the sustainability to the level of 368 
WT control slices (Figs. 7e-f). Taken together, our data demonstrates that AdoCbl is capable of 369 
rescuing the impairment of DAergic neurons in evoked DA release caused by multiple LRRK2 370 
PD mutants.   371 
Discussion   372 
LRRK2 has emerged as a most promising drug target for the treatment of PD. Although 373 
extensive research has yielded potent and selective LRRK2 kinase inhibitors, they are ATP 374 
competitors, some of which are associated with unwanted side effect and unclear clinical 375 
outcome37. Thus, an alternative class of inhibitors should be considered. Herein, we present 376 
evidence that AdoCbl, one of two physiologically active forms of vitamin B12, inhibits LRRK2 377 
kinase activity with a distinct mechanism. Despite the less potent nature in LRRK2 inhibition 378 
compared to many industrially produced compounds, AdoCbl displays a unique feature of 379 
LRRK2 binding and kinase activity modulation mechanism by disturbing LRRK2 protein 380 
conformation or dimerization, which may serve as a base for the development of novel allosteric 381 
inhibitors of LRRK2. Moreover, AdoCbl prevents neurotoxicity and dopamine deficits in animal 382 
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models carrying LRRK2 disease variants. Therefore, our study identifies a novel class of LRRK2 383 
kinase modulator that can be used to probe LRRK2 structure and function relationship and 384 
develop new allosteric LRRK2 inhibitors in the future.  385 
 Our studies demonstrated the ability of AdoCbl to bind directly human LRRK2 through 386 
multiple methods including kinetics, TSA, MST and intrinsic fluorescence (Figs. 1-3). Our data 387 
indicates that AdoCbl acts as a mixed-type allosteric inhibitor capable of affecting ATP binding 388 
to LRRK2. To date, the majority of reported LRRK2 kinase inhibitors has been known as ATP-389 
competitors. Although the structure details of the binding between LRRK2 kinase domain and 390 
the inhibitors are unavailable, insight based on Roco4 kinase studies suggests they are type I and 391 
II inhibitors47,49. These types of inhibitors target the kinase active site; but while Type I bind to 392 
the active conformation, type II bind to the inactive conformation74. Vitamin B12 was shown to 393 
suppress the activity of nitric oxide synthase75 and HIV-1 integrase76, while the ability of B12 to 394 
inhibit kinase activity has never been documented. Indeed, the structure of Vitamin B12 does not 395 
resemble any known kinase inhibitor and no Vitamin B12 mediated kinase inhibition has ever 396 
been reported. In the absence of detailed structural information, our STD-NMR analysis revealed 397 
extensive contacts between vitamin B12 and the Roco4 kinase domain involving the adenosyl 398 
moiety, the bulky corrin ring of cobalamin, and the DMZ base (Fig. 2h). Although ATP and 399 
AdoCbl share an adenosyl moiety, the fact that HOCbl, MeCbl and CNCbl could inhibit LRRK2 400 
kinase activity in vitro with comparable IC50s (Fig. 1) suggests that the (β)-coordinating ligand 401 
in vitamin B12 is not essential for binding to LRRK2. In addition, the ATP-site LRRK2 variant 402 
A2016T, which displays resistance against several ATP-competitive inhibitors such as LRRK2-403 
IN-1 did not have an effect on AdoCbl inhibition in vitro, or in the rescuing by AdoCbl of 404 
behavioral abnormality and DA neuron degeneration in C. elegans expressing LRRK2-405 
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A2016T/G2019S. Thus, our study suggests that vitamin B12 modulates LRRK2 activity by 406 
binding at distinct sites in kinase domain than those for other known LRRK2 inhibitors.  407 
Mechanistically AdoCbl distinguishes itself from other LRRK2 inhibitors by being 408 
capable of altering LRRK2 protein conformation and disturbing LRRK2 dimer status. Several 409 
groups including ours have previously demonstrated that LRRK2 can form dimers12,17,18, which 410 
is thought to represent the kinase active form of LRRK2 in detriment of LRRK2 monomers13. 411 
Since AdoCbl did not affect total LRRK2 levels in cells, it is likely that AdoCbl inhibits LRRK2 412 
kinase activity by shifting the equilibrium from LRRK2 dimers to the kinase inactive monomeric 413 
form (Fig. 4). This hypothesis is consistent with our observation that in contrast to ATP-414 
competitive inhibitors, AdoCbl renders LRRK2 susceptible to proteolysis, as the monomeric 415 
species might be structurally more accessible to proteases than the dimer. Our study also raises a 416 
possibility that AdoCbl prefers dimeric to monomeric LRRK212 for binding. While this idea is 417 
under investigation, our data suggests that the ability of AdoCbl to disrupt dimerization might 418 
offer advantages over known ATP-competitive inhibitors as an allosteric inhibitor to modulate 419 
LRRK2 kinase function. A better understanding of the mode of LRRK2 - vitamin B12 interaction 420 
underlying the mechanism of inhibition of LRRK2 activity will depend on future efforts to solve 421 
the structures of LRRK2-vitamin B12 complexes.  422 
 Compared to the nM inhibition efficacy displayed by the second generation ATP-423 
competitive LRRK2 kinase inhibitors PF-0644747538 and MLi-239, vitamin B12 showed a modest 424 
µM inhibition in vitro. However, it is surprising that the efficacy of AdoCbl in animal models 425 
(Figs. 5-6) was comparable to those high-affinity inhibitors25,30,31. While the unusual increase in 426 
efficacy of AdoCbl inside the cells relative to in vitro condition is surprising and not understood 427 
at present, we speculate that a couple of factors may contribute to the unexpected efficacy of 428 
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AdoCbl in the cells. First, vitamin B12 enters the cells through active transport mediated by 429 
specific proteins transcobalamin and its receptor (CD320), which ubiquitously located on the cell 430 
surface, rather than diffusion (e.g. small compounds)77,78. This mechanism may enhance 431 
intracellular AdoCbl bioavailability, especially in the mitochondria where AdoCbl is normally 432 
located. Second, a potential cell non-autonomous mechanism, where a variety of cells (including 433 
glial cells) produce and secret transcobalamin that could facilitate the uptake of cobalamins in 434 
neurons, may help explain the observation79. Third, vitamin B12 may provide benefits through 435 
acting on additional targets. Thus, the increased efficacy could result from a combination of 436 
multiple target effects including LRRK2 inhibition. Vitamin B12 is capable of crossing the blood 437 
brain barrier (BBB), and it plays a key role in the regulation of excitotoxic homocysteine levels 438 
in the brain80, as well as in the synthesis of fatty acids incorporated into neuronal lipids and 439 
myelin sheaths81. Indeed, vitamin B12 deficiency in humans is known to contribute to a variety of 440 
neurological conditions80,81. Low vitamin B12 levels have been described in patients with 441 
idiopathic PD82-84, and there is also evidence that chronic L-3,4-Dihydroxyphenylalanine (L-442 
dopa) intake decreases vitamin B12 plasma levels
85. A recent study showed that low levels of 443 
vitamin B12 predicts worse motor symptom in early PD
86, however, the mechanism is unknown. 444 
It is likely that vitamin B12 supplement provides some benefit in PD 
84,88, but the lack of 445 
knowledge of bioavailability of specific forms of vitamin B12 (particularly in CNS) due to the 446 
limitation of measurements hinders the understanding of the beneficial effect of vitamin B12 in 447 
human tissues.  448 
Although it is challenging to understand the benefit or therapeutic potential of vitamin 449 
B12 in PD due to above obstacles, our study implies inhibition of LRRK2 through vitamin B12 as 450 
a potential mechanism. Our observation raises a possibility that tissue levels of AdoCbl 451 
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(including CNS and peripheral tissues) might modulate disease penetrance or progression of 452 
LRRK2 variants in light of current reports showing the involvement of peripheral tissue/cells in 453 
LRRK2 related pathogenesis87-90. Related epidemiologic studies should be performed in the near 454 
future to address the possible association91. Indeed, future studies should investigate biochemical 455 
and structural basis underlying the modulation of LRRK2 activity by vitamin B12 as well as 456 
vitamin B12 efficacy and bioavailability in tissues in order to understand the therapeutic potential 457 
of vitamin B12 in PD. Nonetheless, AdoCbl represents a starting point for the development of a 458 
new class of LRRK2 activity modulators (e.g. allosteric inhibitor) for the much-needed treatment 459 
of LRRK2-linked pathological conditions such as PD and inflammatory bowel disease (IBD)92.  460 
 461 
 462 
 463 
 464 
 465 
 466 
Materials and Methods 467 
Chemicals 468 
The FDA-approved chemical library used for the primary screen at the Mount Sinai Integrated 469 
Screening Core was purchased from Microsource Discovery (Gaylordsville, CT, USA) and 470 
contained 2,080 bioactive compounds approved for use in humans or animals. Trypsin, ATP, 471 
AMP-PNP, and all forms of cobalamin were purchased from Sigma Aldrich (St. Louis, MO, 472 
USA). All experiments involving AdoCbl were performed under light-protected conditions to 473 
reduce photolability. GNE-1023 was kindly gifted to us by Genentech (South San Francisco, CA, 474 
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USA). The inhibitors GSK2578215A, PF-06447475, and MLi-2 were purchased from Tocris 475 
(Bristol, UK). Bovine purified myelin basic protein was obtained from EMD Millipore 476 
(Darmstadt, Germany) and purified Rab10 was purchased from Origene (Rockville, MD, USA). 477 
Purified full-length flag-tagged LRRK2 was purchased from Invitrogen (Carlsbad, CA, USA).  478 
 479 
Antibodies 480 
Anti-LRRK2 N241A/34 NeuroMab clone was obtained from the Michael J. Fox Foundation, 481 
anti-pS93544 LRRK2 (ab133450) was from Abcam, and anti-pS129220 was kindly gifted by 482 
Genentech. Anti-Rab10 (8127) was purchased from Cell Signaling and anti-pRab10 pT73 was 483 
obtained from the University of Dundee, UK.  484 
 485 
Protein Purification 486 
BAC-transgenic mouse brain overexpressing flag-tagged LRRK2 was homogenized in 487 
homogenization buffer (20 mM HEPES at pH 7.4, 0.32 M Sucrose, 1 mM NaHCO3, 0.25 mM 488 
CaCl2, 1 mM MgCl2, 1 mM PMSF, and complete protease inhibitor cocktail), then Triton X-100 489 
was added to a final concentration of 1% and incubated at 4°C on a rotator for 30 min. 490 
Homogenized brain was clarified at 12,000 x g for 10 min at 4°C and the FLAG-LRRK2 protein 491 
were purified using Anti-FLAG Affinity Gel (Sigma, A220) with extensive wash before elution. 492 
The protein was eluted using 150 ng/µL FLAG-peptide (Sigma, F4799) and stored at 80°C until 493 
use. 494 
 495 
The human LRRK2 pDEST-NSF-tandem affinity plasmid was kindly gifted by Dr. Christian 496 
Johannes Gloeckner (University of Tubingen, Germany). Strep-tagged LRRK2 was expressed in 497 
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HEK293T cells through transient transfection for 48 hours, as described previously12. Cells were 498 
harvested and incubated in lysis buffer (50 mM Tris pH 7.5, 100 mM NaCl, 2 mM DTT, 5 mM 499 
MgCl2, 0.5 mM EGTA, 1% Triton X-100, 10% Glycerol, Roche protease inhibitors 500 
(11836170001)) for 30 minutes at 4°C. Lysate was centrifuged at 13,000 x g for 15 minutes. 501 
Supernatant was mixed with Strep-Tactin Sepharose (2-1206-002) from Iba Life Sciences for 2 502 
hours and washed extensively with buffer above, substituting 0.02% Triton X-100 for 1%. Strep-503 
Flag LRRK2 was eluted using 10mM desthiobiotin and stored at 80°C until use. 504 
 505 
The 6xHis-GST-tagged Roco4 kinase domain plasmid, kindly gifted by Dr. Andy West 506 
(University of Alabama Birmingham, AL, USA), was transformed into BL21 (DE3) cells 507 
(Agilent Technologies, 230132) and grown at 37°C in 2xYT broth until reaching an OD600 of 508 
0.6. Overexpression was induced for 16 hours at 18°C with 300 µM IPTG. Cells were pelleted 509 
and resuspended in 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM TCEP, 0.02% Reduced TX100, 1 510 
mM PMSF, 25 µg/mL lysozyme, 4 ug/mL DNase. Protein was bound to Ni-NTA resin and 511 
washed and eluted with increasing concentrations of imidazole. Protein was concentrated and 512 
treated with TEV protease to cleave the 6xHis-GST tag, while dialyzing in buffer overnight to 513 
remove imidazole. 6xHis-GST tag was separated using Ni-NTA resin and pure Roco4 kinase 514 
domain was collected in the flow through.  515 
The pGEX-6p-1 construct was expressed as above using BL21 (DE3) cells. Crude lysate was 516 
bound to Glutathione Sepharose 4B (17-0618-01, GE Healthcare) for 1 hour before beads were 517 
washed 3x with PBS. GST protein was eluted with reduced glutathione.  518 
 519 
Compound Screen and TR-FRET Kinase Assay 520 
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Compounds from the FDA-Approved library were tested against flag-tagged LRRK2 purified 521 
from BAC transgenic mouse brain. LRRK2 kinase activity was monitored by measuring time 522 
resolved fluorescence resonance energy transfer (TR-FRET) emission ratio upon the 523 
phosphorylation of Fluorescein-LRRKtide (PV4901, Invitrogen) and subsequent binding of 524 
Terbidium-pLRRKtide antibody (PV4898, Invitrogen). This TR-FRET-based assay was used in 525 
a high-throughput screen (HTS) of small molecule chemical compounds for LRRK2 using the 526 
TECAN (Mannedorf, Switzerland) Freedom EVO 200 liquid handling system, and relative 527 
fluorescence was measured using the TECAN Safire 2 fluorescence spectrometer. To determine 528 
the TR-FRET ratio between Fluorescein-LRRKtide and Terbidium-pLRRKtide antibody, 529 
fluorescent intensity was measured at wavelengths 515 nm and 485 nm.  530 
Prior to the HTS, each compound was prepared at 4x final concentration (1.6 or 4% 531 
residual DMSO volume) in Kinase Buffer S, containing 50 mM Tris pH 8.5, 10 mM MgCl2, 532 
0.01% Brij-35, 1 mM EGTA in 96-well polypropylene non-treated plates (Thermo Scientific, 533 
#12-565-436). The kinase reaction was performed in 10 µl total volume in a low-volume white 534 
384-well plate (Corning, #3673), with 20 nM LRRK2, 400 nM Fluorescein-ERM (LRRKtide), 535 
and small molecules in Kinase Buffer S supplemented with 2 mM DTT on the day of the 536 
experiment. Small molecules were screened at 3.3 or 4 µM with 0.4 or 1% residual DMSO in 537 
duplicate. The assay plates were prepared by adding 2.5 µl of 4x compound solutions, 2.5 µl of 538 
4x LRRK2, and 5 µl of 2x LRRKtide and ATP mixture. After incubation at room temperature 539 
for 4 hours, the kinase reaction was terminated by the addition of 10 µl of 2x EDTA and 2x Tb-540 
anti-pERM antibody in the detection buffer, containing 20 mM Tris-HCl, 0.01% NP40. EDTA 541 
was mixed with the antibody right before the addition of the mixture to wells, as the antibody 542 
was stable in EDTA only for several hours. The final concentration of EDTA and Tb-anti-pERM 543 
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were 5 mM and 2.5 nM, respectively. After 1-hour incubation at room temperature, TR-FRET 544 
measurements were obtained according to the parameters described in instrument settings. 545 
During the incubation, 384-well plates were covered by aluminum sealing tapes (Corning, 546 
#6570) to reduce evaporation and exposure to light. All the liquid handling was carried out using 547 
fixed 8-tip LiHa arms on TECAN EVO200 workstation. HTS was performed with 0.4 or 1% 548 
DMSO as negative control and no LRRK2 as positive control. Hit compounds were selected 549 
based on the normalized percent inhibition by first computing emission ratio (emission intensity 550 
of acceptor divided by donor) and then computing percent inhibition of kinase activity relative to 551 
the DMSO treated control as 0% inhibition and the control in the absence of LRRK2 as 100% 552 
inhibition. Compounds in wells showing greater than 30% inhibition in either of the duplicates 553 
were selected as hits. 554 
 555 
In Vitro Kinase Assays 556 
Kinase reactions were performed in 30 uL kinase buffer (20 mM Tris pH 7.5, 1 mM DTT, 15 557 
mM MnCl2, 20 mM ȕ-glycerophosphate) at 37°C for 30 minutes in the presence of [Ȗ-32P] ATP 558 
(3000 Ci/mmol; BLU502H250UC, PerkinElmer Life Sciences) and 50 µM cold ATP. 559 
Beforehand, LRRK2 or Roco4 Kinase was loaded with inhibitor and/or substrate, followed by 30 560 
min incubation on ice. Reactions were stopped by addition of Laemmli buffer and boiling at 561 
95°C for 10 minutes. Samples were resolved on 4-12% SDS-PAGE pre-cast gels (NP0323BOX, 562 
Invitrogen). Radioactive signal was captured onto a phosphor-screen (S0230, GE Lifesciences) 563 
and was digitally collected using a Typhoon scanner. ImageQuant densitometry was used to 564 
quantify the phosphor-signal.  565 
 566 
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GTP Hydrolysis Assay 567 
GTPase activity of strep-tagged LRRK2 was measured in 30 uL GTPase buffer (20 mM Tris pH 568 
7.5, 150 mM NaCl, 1 mM DTT, 5 mM MgCl2, 1 mM EDTA) at 30°C for 90 minutes. LRRK2 569 
was incubated with inhibitor for 30 min on ice before reactions were initiated with the addition 570 
of 50 µM cold GTP and [Į-32P] GTP (3000Ci/mmol; BLU006H250UC, PerkinElmer Life 571 
Sciences). Reactions were terminated with the addition of 0.5 M EDTA. 2 uL of the reaction 572 
mixture were dotted onto TLC plates (M1055790001, EMD Millipore). GDP and GTP were 573 
separated by TLC using 0.5 M KH2PO4 pH 3.5 for 60 minutes. The TLC plate was dried for 15 574 
minutes and radioactive signal was captured and using a phosphor-screen and a Typhoon 575 
scanner. ImageQuant densitometry was used to quantify the phosphor-signal.  576 
 577 
B12-Agarose Binding Assay 578 
500 µL of 40 nM strep-tagged LRRK2 or 500 uL of 100 nM GST, pre-loaded with AdoCbl or 579 
buffer for 30 min on ice, were incubated with 50 uL B12-Agarose (V3254, Sigma Aldrich). B12-580 
Agarose was washed 3x with buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM TCEP, 581 
0.02% Triton X-100, 1% Ficoll 400) and bound protein was eluted with Laemmli buffer and 582 
boiling at 95°C. Bound LRRK2 or GST was analyzed by western blot.  583 
 584 
Thermal Shift Assay 585 
300 nM strep-tagged LRRK2 was incubated with Sypro Orange and inhibitor or buffer to a final 586 
volume of 30 uL. Using a Stratagene Mx3000 Real-time PCR machine, samples were heated to 587 
95°C and fluorescence intensity of Sypro Orange was measured at every 0.5°C increment. For 588 
each experiment, data was normalized to the maximum fluorescent intensity. 589 
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 590 
Microscale Thermophoresis 591 
Microscale Thermophoresis (MST) measurements were obtained using a Monolith NT.115 592 
(NanoTemper Technologies). Purified strep-tagged LRRK2 was labeled with NT-647 dye 593 
(NanoTemper Technologies) and experiments were performed using a 2 nM final concentration. 594 
A 12-point dilution series of AdoCbl, ranging from 200 nM to 100 µM, was added to labeled 595 
LRRK2. After 30 min incubation on ice, the binding reaction was loaded onto Standard 596 
capillaries (NanoTemper Technologies) and measurements were taken using 30% LED power 597 
and 50% MST power. Laser on-time was set to 30 seconds and laser off-time was set to 5 598 
seconds. Data was processed using GraphPad Prism 6.0 and a KD was derived from three 599 
independent thermophoresis experiments by fitting a curve based on the law of mass action. 600 
Quality of each MST run was assessed by performing a capillary scan before and after each data 601 
collection to check that the fluorescence between samples stays within ± 10%. Furthermore, each 602 
time-trace showed a smooth decrease in normalized fluorescence, suggesting that no 603 
precipitation occurred during the experiments.  604 
 605 
STD-NMR 606 
Saturation Transfer Difference (STD) NMR was carried out with 1024 scans on a Bruker 607 
800MHz NMR spectrometer equipped with a cryogenic probe at 277 K according to Mayer et 608 
al93. Saturation on and off frequencies were set to -1 and -20 ppm, respectively, with saturation 609 
achieved using a 2 s train of 50 ms Gaussian pulses at 86 Hz. 1024 scans were used. STD-NMR 610 
samples contained 50 mM Tris, 150 mM NaCl, 1 mM TCEP and 2 mM MgCl2 at a pH of 7.5, 611 
 27
20-30 µM Roco4 protein, with vitamin B12 at 100-fold excess over Roco4 in concentration. 612 
Vitamin B12 resonances were assigned in D2O according to Summers et al
94.  613 
 614 
Intrinsic Fluorescence 615 
Strep-tagged LRRK2 at a concentration of 150 nM was incubated with AdoCbl or buffer in a 616 
total volume of 80uL. Samples were loaded onto a 96-well black-walled plate and fluorescence 617 
was measured using a Tecan Safire microplate reader. For these experiments, a correction 618 
equation must be applied to the fluorescent measurements to compensate for the inner filter 619 
effect. AdoCbl absorbs light at 295 nm, which affects the excitation strength of the incident light, 620 
and from 340-360 nm, which affects the amount of light reaching the detector after tryptophan 621 
emission. Therefore, we calculated a corrected fluorescence value (Supplementary 622 
information, Figs. S5c-d) for each sample by measuring the absorbance at the excitation and 623 
emission wavelengths and multiplying by the original fluorescence value 95.  624 
 625 
Limited Proteolysis Assays 626 
Strep-tagged LRRK2 or TBK1 was subjected to limited proteolysis by trypsin or chymotrypsin 627 
with a 10:1 molar ratio of LRRK2 to protease at 37°C. LRRK2 was loaded with inhibitor for 30 628 
min on ice before protease was added. Reactions were stopped with the addition of Laemmli 629 
buffer and boiling at 95°C.  630 
 631 
In situ labeling and detection of LRRK2 dimers.  632 
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For the biochemical detection and purification of biotinylated LRRK2 dimers, we used an 633 
adaptation of the proximity biotinylation approach96. A manuscript describing the full 634 
characterization of this assay is currently under review (Leandrou et al.; submitted to Biochem 635 
J). HEK293T cells, maintained throughout the duration of the experiment in biotin-depleted 636 
media, were co-transfected with plasmids encoding WT LRRK2, fused to biotin ligase (BirA) or 637 
an acceptor peptide (AP). The following day, the growth media was replaced and the indicated 638 
concentrations of AdoCbl, diluted in media, were added, and the cultures maintained for an 639 
additional 48h. Prior to cell lysis, the cells were washed in pre-warmed PBS and given a brief (5 640 
min) pulse with 50 µM biotin, followed extensive washing with PBS. Cytoplasmic extracts were 641 
prepared in lysis buffer (20mM HEPES, pH 7.4; 150 mM NaCl; 0.5% NP-40; 2mM EGTA; 2 642 
mM MgCl2; 10% glycerol; pH 7.2). Following lysis, 5 µg of total clarified cell extract was bound 643 
to streptavidin-coated ELISA plates for 1h at 37ºC under constant agitation. The supernatant was 644 
removed and retained, and the wells were washed, and the amount of biotinylated LRRK2 645 
present in each sample was quantified using HRP-conjugated (in house) anti-LRRK2 (75-253, 646 
NeuroMab/Antibodies Incorporated; clone N241A/B34). Duplicate samples were incubated in 647 
the parallel ELISA plates pre-coated with anti-LRRK2 (ab195024, Abcam) in order to quantify 648 
the total amount of LRRK2 present in each sample. In each experiment, control samples were 649 
prepared from cells co-expressing AP-LRRK2 together with Flag-LRRK2 (without the BirA 650 
biotin ligase). To visualize expression of both LRRK2 constructs, parallel extracts were 651 
separated by SDS-PAGE (6%), and membranes probed with anti-LRRK2 (clone N241A/B34). 652 
 653 
Generation of Mouse Embryonic Fibroblasts (MEFs) 654 
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LRRK2-G2019S and wild type control MEFs were isolated from mouse embryos at day E13.5 655 
resulting from crosses between heterozygous LRRK2-G2019S and wild type C57/BL/6J mice. 656 
All the MEFs were cultured for at least 30 passages to immortalize the cells. All cells were 657 
cultured in DMEM containing 10% FBS, 2mM L-glutamine and 100 units/ml Penicillin-658 
Streptomycin, and were maintained at 37°C with 5% CO2. All cells lines were confirmed by 659 
PCR genotyping and western blot, but were not tested for mycoplasma contamination. To test 660 
inhibition, cells were treated with inhibitor or DMSO for 24 hours in DMEM with 3% FBS 661 
before being lysed and subject to western blot for analysis.  662 
 663 
Treatment of C. elegans with AdoCbl 664 
C. elegans strains were cultured on standard nematode growth medium (NGM) agar plates 665 
seeded with E. coli OP50 as a food source. Mixed stage animals were maintained as bulk culture 666 
on NGM agar at room temperature (22oC). Prior to each experiment, animals were age-667 
synchronized by standard bleaching and washing protocol to obtain embryos, from which 668 
developmental stages were followed. The following transgenic C. elegans lines expressing green 669 
fluorescent protein (GFP) either alone (SGC730: Pdat-1::GFP) or together with human LRRK2-670 
G2019S (SGC856: Pdat-1::LRRK2-G2019S; Pdat-1::GFP) or human LRRK2-R1441C (SGC851: 671 
Pdat-1::LRRK2-R1441C Pdat-1::GFP) in dopaminergic neurons were used63.  672 
 673 
Treatment with AdoCbl was done in liquid culture to ensure adequate drug exposure using the 674 
published protocol as described30. Briefly, worms were age-synchronized to generate L1 larva in 675 
M9 buffer [For 1 liter: KH2PO4, 3 g; Na2HPO4, 6 g; NaCl, 5 g; MgSO4 (1 M), 1 ml], which 676 
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were distributed into a 12-well microtiter plate seeded with E. coli OP50 with roughly 50 L1 677 
worms in a total volume of 900 ml. AdoCbl stock made in water was added to achieve the 678 
desired concentrations. The 12-well plate was covered in aluminum foil to protect from light, 679 
maintained in a humidified chamber at room temperature and shaken at 100 rpm. Worms were 680 
monitored every day and placed onto agar plates with OP50 when most of them reached L4 681 
larval stage (about 3 days). L4 worms were grown on NGM agar plates seeded with E. coli OP50 682 
for 3 days for behavioral assay or 9 days for neuronal assessment as described below.  683 
 684 
C. elegans Basal Slowing Assay 685 
Well-fed worms with intact dopaminergic neural circuitry move slower in the presence of 686 
bacterial food than in its absence64. This basal slowing response was assayed as described 687 
previously63,64. Briefly, a set of NGM assay plates were seeded with bacterial food, E. coli OP50, 688 
in a ring shape, and another set of NGM assay plates were uncoated. Age-synchronized worms 689 
(about 10 worms of each strain) were washed twice in S basal buffer (100 mM NaCl, 10 mg/ml 690 
cholesterol, 50 mM potassium phosphate, pH 6.0). Worms were then transferred to the center of 691 
the NGM plates coated with or without E. coli OP50 as described above, settled for 5 min, and 692 
their locomotion were recorded with a digital camera in 20 s intervals. Body bends were 693 
examined using an unbiased machine-vision analysis system (WormLab, MBF Bioscience, 694 
Williston, VT). Basal slowing was calculated as the percent slowing in body bends per 20 s in 695 
the presence vs. the absence of bacterial lawn.  696 
 697 
Assessment of Dopaminergic Neuron Survival in C. elegans 698 
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Dopaminergic neurons in live C. elegans were examined essentially as described63. Briefly, 699 
worms were immobilized in the presence of 3 mM levamisole and were mounted on glass slides. 700 
The dopaminergic neurons in the head regions [four cephalic neurons (CEPs)] were visualized 701 
for GFP fluorescence under a Zeiss Axiovert 200M microscope. The total numbers of CEPs with 702 
the intact cell body (survived) as well as those missing most of the cell body and neurites 703 
(degenerated) were counted. For each strain, about 30 worms were analyzed in at least three 704 
independent experiments. The percent of dopaminergic neuron survival was calculated as the 705 
number of intact CEPs observed in all animals divided by total number of CEPs expected if no 706 
degeneration occurred (four in each animal times the number of animals tested), times 100. 707 
Fluorescent images of DA neurons in the head region of worms were taken with a Zeiss Axiovert 708 
200M microscope using 1 s exposure time at 20× magnification.  709 
 710 
Sample size was determined according to the Statistical Solutions LLC calculator 711 
(http://www.statisticalsolutions.net/pssTtest_calc.php).  Assuming alpha value of 0.05, to detect 712 
difference of 10% between 100% mean for the control group and 90% mean for an experimental 713 
group, 5% expected standard deviation (two-sided t-test), and a power of 0.8, a sample site of 4 714 
animals is obtained. In Fig. 4, more than 20 worms were used for each group. All live and age-715 
synchronized worms were included in the experiments. Only dead worms, if any, were excluded. 716 
The number of worms available for experiments was in general five times more than the number 717 
of worms being assayed (e.g., 20 worms were randomly picked for from a culture of 100 718 
worms). For these experiments, the investigator was not blinded to group allocations. Data is 719 
normally distributed, and the variance was similar between the groups that are being statistically 720 
compared. 721 
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 722 
Treatment of Drosophila with AdoCbl 723 
Flies were used and raised as described recently31. Briefly, the TH (tyrosine hydroxylase) GAL4 724 
was crossed with either UAS-hLRRK2-wildtype, UAS-hLRRK2-G2019S or the kinase-dead 725 
UAS-hLRRK2-G2019S-K1906M line to produce progeny dopaminergic expression of the 726 
transgene (DA → hLRRK2, DA → G2019S, DA → KD). The crosses were allowed to lay eggs 727 
onto instant fly food (Carolina) or onto instant food supplemented with AdoCbl. The final 728 
concentration of AdoCbl in the fly food ranged from 100 to 2500 nM. Females were collected on 729 
the day of emergence and transferred to new vials (no AdoCbl) for 24 hours. In control 730 
experiments, low expression dLRRK flies (dLRRKe03680) were fed instant fly food or food 731 
supplemented with AdoCbl. 732 
 733 
Physiological recordings: 18-24 hour old females were aspirated in a pipette tip, restrained with 734 
nail polish, and allowed to recover for >20 minutes. A recording electrode was placed in the 735 
center of the eye, and a reference electrode in the mouthparts. After 2 minutes in the dark, the fly 736 
was illuminated with light from a blue flickering LED and the resulting electroretinogram signal 737 
amplified and stored for off-line analysis. The response was analyzed by the Fast Fourier 738 
Transform (FFT), generating components corresponding to the photoreceptors, second order 739 
lamina neurons, and third/fourth order medulla neurons. Stimulus generation, recording and 740 
analysis were accomplished in Matlab, as described recently31; Matlab code available at 741 
https://github.com/wadelab/flyCode). The number of flies used was sufficient according to 742 
previously published data31. All data from tested flies were included. Male and female flies of 743 
the required genotype were placed in randomly chosen vials (+/- drug) and allowed to mate and 744 
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lay eggs. Offspring were harvested daily and flies were sampled at random. The investigators 745 
were blinded to the genotype while the experiments were in progress. For statistical analysis, 746 
estimates of variation were made and are similar between groups being compared.  747 
 748 
Determination of Survival of Primary Cortical Neurons  749 
Primary rat embryonic cortical neurons were prepared and cultured as described70,97. Briefly, 750 
embryonic day 17 rat cortices were dissociated and plated on poly-d-lysine coated 12mm 751 
diameter glass coverslips in Neurobasal medium (12348017, Invitrogen-ThermoScientific) with 752 
B-27 serum free supplements (17504044, Invitrogen-ThermoScientific) at a density of 125,000 753 
neurons per cm2. On day four following plating, neurons were transiently co-transfected with 754 
LRRK2-WT or LRRK2-G2019S and pcms-EGFP at a ratio of 4:1 using Lipofectamine 2000 755 
according to the manufacturers instructions. The indicated concentrations of AdoCbl or MLi-2 756 
in Neurobasal/B-27 medium was added to the neurons on the morning following transfection and 757 
supplemented one additional time at the mid-point (36 h) of the total duration of the experiment. 758 
Following a period of 72 h of expression, the coverslips were fixed in 4% formaldehyde and 759 
stained with anti-GFP antibodies (ab13970, Abcam) and DAPI. We had determined in parallel 760 
neurons double stained with GFP and anti-LRRK2 antibodies (ab133474, Abcam) that the 761 
percentage of GFP-positive neurons over-expressing LRRK2 was approximately 90% (not 762 
shown). To simplify quantification of apoptotic degenerating neurons, GFP-positive neurons 763 
were visualized and determine to be apoptotic or viable. For quantification, apoptotic neurons 764 
were defined as those having condensed fragmented chromatin comprised of two or more 765 
apoptotic bodies. More than 100 neurons per coverslip were assessed in triplicate coverslips in a 766 
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blinded fashion, from two to three independent cultures. The data are presented as the percentage 767 
of GFP-positive neurons containing apoptotic nuclear features. 768 
 769 
Animals and Brain Slice Preparation 770 
The use of the animals followed the National Institutes of Health guidelines and was approved 771 
by the Institutional Animal Care and Use Committee at Thomas Jefferson University. All efforts 772 
were made to minimize the number of animals used. BAC LRRK2(hR1441G) transgenic (TG) 773 
mice were obtained from Chenjian Lis laboratory at Weill Medical College of Cornell 774 
University and maintained on Taconic FVB/N background and BAC LRRK2(G2019S) TG mice 775 
previously described19 maintained on C57/NJ background. 776 
Three- to 5-month-old male transgenic LRRK2-G2019S mice and their non-transgenic 777 
littermates were used for LRRK2 kinase inhibition in striatal brain slices. For preparing striatal 778 
slices, mice were decapitated without anesthesia after cervical dislocation and brains were 779 
immediately dissected out. Coronal striatal brain slices at 250 ȝm were prepared on a vibratome 780 
(VT1200, Leica, Solms, Germany). The striatal slices were allowed to recover for 0.5 to 1 hour 781 
at 36°C in a holding chamber containing oxygenated artificial CSF (ASCF: 125 mM NaCl, 2.5 782 
mM KCl, 26 mM NaHCO3, 2.4 mM CaCl2, 1.3 mM MgSO4, 0.3 mM KH2PO4, and 10 mM 783 
glucose, pH 7.3-7.4). To examine the effects of the LRRK2 inhibitors, slices were incubated for 784 
2 h in oxygenated ACSF containing LRRK2 inhibitors. For the incubation treatment, striatal 785 
slices were bisected, and one striatum was exposed to LRRK2 inhibitor (2 h) while the other was 786 
exposed to vehicle (DMSO or water). After treatment, the slices were collected and rapidly 787 
frozen in dry ice and stored in -80°C until assayed. 788 
 789 
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Slice Preparation for Evoked DA Transmission 790 
Twelve- to 15-month-old male LRRK2-G2019S as well as 6- to 14-month-old male 791 
LRRK2-R1441G BAC transgenic mice and their age-matched non-transgenic littermates were 792 
used. For preparing striatal slices, mice were decapitated without anesthesia after cervical 793 
dislocation and brains were immediately dissected out. Coronal striatal brain slices at 250 ȝm 794 
were prepared on a vibratome (VT1200, Leica, Solms, Germany) for electrophysiological 795 
recording. The striatal slices were allowed to recover for at least 1 hour at 36°C in a holding 796 
chamber containing oxygenated artificial CSF (ASCF) and then placed in a recording chamber 797 
superfused (1.5 ml/min) with ACSF at 36°C. The pH of all ACSF solutions were adjusted to 7.3798 
7.4 with concentrated hydrochloric acid and ACSF solutions were saturated with carbogen (95% 799 
O2/5% CO2) prior to use to ensure stable pH buffering and adequate oxygenation. 800 
Striatal slices were bisected, and one striatum was incubated for 2 hours in ACSF at 36°C 801 
containing 300 µM AdoCbl while the other was exposed to vehicle (water) as the control. Slices 802 
were washed with ACSF for 20 min after treatment before fast scan cyclic voltammetry (FSCV) 803 
recording. 804 
 805 
Fast scan cyclic voltammetry recording (FSCV) 806 
FSCV was used to measure evoked DA release in the dorsal striatum (dSTR). Electrochemical 807 
recordings and electrical stimulation were performed as previously described73. Briefly, freshly 808 
cut carbon fiber electrodes ~5 µm in diameter were inserted ~50 µm into the dSTR slice. For 809 
FSCV, a triangular voltage wave (-400 to 900 mV at 280 V/sec versus Ag/AgCl) was applied to 810 
the electrode every 100 msec. Current was recorded with an Axopatch 200B amplifier (Axon 811 
Instruments, Foster City, CA), with a low-pass Bessel filter set at 10 kHz, digitized at 25 kHz 812 
(ITC-18 board; InstruTech, Great Neck, NY). Triangular wave generation and data acquisition 813 
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were controlled by a personal computer running a locally written (Dr. E. Mosharov, Columbia 814 
University, New York, NY) IGOR program (WaveMetrics, Lake Oswego, OR). Striatal slices 815 
were electrically stimulated (400 ȝA x 1 ms pulse duration) by an Iso-Flex stimulus isolator 816 
triggered by a Master-8 pulse generator (AMPI, Jerusalem, Israel) using a bipolar stimulating 817 
electrode placed at a distance of ~150 µm from the recording electrode. The slices were 818 
stimulated every 2 min. Background-subtracted cyclic voltammograms served for electrode 819 
calibration and to identify the released substance. DA oxidation current was converted to 820 
concentration based upon a calibration of 5 µM DA in ACSF after the experiment. For each 821 
experimental condition, at least three slices from at least three different mice were examined 822 
unless specified otherwise. The number of the recording sites was determined according to 823 
previously published experiments19 and SSD sample size power analysis. No randomization and 824 
no blinding were used for experimental groupings. All recorded data was included. Statistical 825 
tests were justified as appropriate, as data meets test assumptions, with a similar estimated 826 
variance between groups that are statistically compared. 827 
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Glossary of Terms 867 
ACSF: artificial cerebrospinal fluid 868 
AdoCbl: 5-deoxyadenosylcobalamin, or adenosylcobalamin 869 
AP: acceptor peptide 870 
a.u.: arbitrary unit 871 
BirA: biotin ligase 872 
BAC: bacterial artificial chromosome 873 
CEP: cephalic neurons 874 
CNCbl: cyanocobalamin 875 
CRF: contrast response function 876 
DAergic: dopaminergic 877 
DMZ: dimethylbenzimidazole 878 
FFT: fast Fourier transform 879 
 880 
FSCV: fast scan cyclic voltammetry 881 
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HOCbl: hydroxycobalamin 882 
HTS: High-throughput Screen 883 
LRRK2: Leucine-Riche Repeat Kinase 2 884 
MBP: myelin basic protein 885 
MeCbl: methylcobalamin 886 
MEF: mouse embryonic fibroblast 887 
MST: microscale thermophoresis 888 
PD: Parkinsons Disease 889 
STD-NMR: saturation transfer difference nuclear magnetic resonance 890 
TR-FRET: time-resolved fluorescence resonance energy transfer 891 
TSA: thermal stability assay 892 
WT: wild-type 893 
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 1186 
Fig. 1. AdoCbl inhibits LRRK2 kinase activity. (a) Domain structure of LRRK2. (b) Dose-1187 
response curves of brain-purified flag-tagged LRRK2 kinase as a function of different forms of 1188 
 45
cobalamin. Phosphorylation is quantified by measuring TR-FRET emission ratios of fluorescein-1189 
LRRKtide and a Terbidium-labeled pLRRKtide antibody. (c) Dose-response curves of strep-1190 
tagged LRRK2 autophosphorylation or (d) phosphorylation of myelin basic protein as a function 1191 
of different forms of cobalamin. (e) Dose-response curve of strep-tagged LRRK2-G2019S 1192 
phosphorylation of purified Rab10 as a function of AdoCbl. (f) Dose-response curves of 1193 
pS935/Total LRRK2 and (g) pS1292/Total LRRK2 after treatment with different forms of 1194 
cobalamin in MEF cells derived from LRRK2-G2019S BAC transgenic mice. Data from each 1195 
replicate was normalized to LRRK2 phosphorylation without cobalamin treatment. All data 1196 
points represent the mean (± s.d.) of three biological replicates. 1197 
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 1209 
Fig. 2. Direct binding of AdoCbl to LRRK2 protein. (a) Binding of strep-tagged LRRK2 to 1210 
AdoCbl-agarose in the presence of AdoCbl. Input represents the amount of protein that was 1211 
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added to beads, while pull-down denotes the amount of protein left on the beads after washes. 1212 
Significance was calculated by one-way ANOVA using the mean (± s.d.) of three biological 1213 
replicates. * p  0.05, ** p  0.005 (b) Thermal shift assays showing melting temperatures of 1214 
strep-LRRK2 in the presence of AdoCbl or PF-06447475. (c) Microscale thermophoretic 1215 
analysis of the interaction between AdoCbl or (d) PF-06447475 with strep-tagged LRRK2. (e) 1216 
Coomassie stained SDS-PAGE of the Roco4 kinase domain purified from E. coli. (f) Dose-1217 
response curve of Roco4 kinase activity as a function of AdoCbl. (g) ATP STD-NMR shows 1218 
direct binding of AdoCbl to the Roco4 kinase domain and competition with ATP. From top to 1219 
bottom, the spectra are as follows: 1D 1H NMR of ATP (blue), AdoCbl (red), STD negative 1220 
control with ATP + AdoCbl only (green), STD positive control with ATP and Roco4 kinase 1221 
domain (orange), STD of AdoCbl and Roco4 kinase domain with 1:1 ratio of AdoCbl to ATP 1222 
(purple), and STD of AdoCbl and Roco4 kinase domain with 10:1 ratio of AdoCbl to ATP 1223 
(yellow). AdoCbl protons showing strong STD signals are labeled with assignment. All 1224 
experiments were collected at 4°C on a Bruker 800MHz spectrometer equipped with a 1225 
cryoprobe. (h) Protons with strong STD signals (highlighted in red) mapped onto the structure of 1226 
AdoCbl. The NMR assignment and nomenclature of vitamin B12 is from Summers et al.94 Data 1227 
points in (a,c,d,f) represent the mean (± s.d.) of three biological replicates. 1228 
 1229 
 1230 
 1231 
 1232 
Fig. 3. AdoCbl exhibits a mixed-mode of inhibition. (a) Michaelis-Menten kinetics curves of 1233 
full-length Invitrogen flag-tagged LRRK2-WT and (c) LRRK2-G2019S as a function of AdoCbl. 1234 
 47
Relative velocity represents the value of pS1292/Total LRRK2 after 20 minutes of reaction time 1235 
at 30°C (during the linear reaction rate), as detected by western blot and quantified by 1236 
densitometry. (b) Lineweaver-Burk plots of LRRK2-WT and (d) LRRK2-G2019S kinetics data. 1237 
(e) Microscale thermophoretic analysis of the interaction between AdoCbl and strep-tagged 1238 
LRRK2 in the presence of increasing concentrations of AMP-PNP. Fluorescently-labeled strep-1239 
tagged LRRK2 was pre-incubated with AMP-PNP before binding between LRRK2 and AdoCbl 1240 
was measured by MST. (f) Microscale thermophoretic analysis of the interaction between AMP-1241 
PNP and LRRK2, showing a KD of 0.9 ƫM. Data points represent the mean (± s.d.) of three 1242 
biological replicates.  1243 
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 1249 
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 1254 
 1255 
Fig. 4. AdoCbl causes a LRRK2 conformational change and destabilizes LRRK2 dimers. 1256 
(a) Coomassie stained SDS-PAGE showing limited proteolysis analysis using a 10:1 molar ratio 1257 
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of LRRK2: Trypsin (left panel) and LRRK2: Chymotrypsin (right panel). Proteolysis was 1258 
performed at 30°C with or without 50 µM AdoCbl and reactions were quenched at the indicated 1259 
times by the addition of sample loading buffer. The observed data was consistent across three 1260 
biological replicates. (b) Limited proteolysis of LRRK2-WT by trypsin in the presence of 1261 
increasing concentrations of AdoCbl, or 1 µM LRRK2 kinase inhibitor. Proteolysis was 1262 
performed for 90 minutes at 30°C. Shown is a representative SDS-PAGE of full-length LRRK2, 1263 
in which bands were quantified and values were normalized to LRRK2 proteolysis without 1264 
AdoCbl. (c) The peak intrinsic fluorescence of LRRK2 (339 nm) was measured as a function of 1265 
AdoCbl. Strep-tagged LRRK2 was incubated with indicated concentrations of AdoCbl for 30 1266 
minutes prior to fluorescence measurements. Significance was measured by one-way ANOVA. * 1267 
p  0.05, ** p  0.005. (d) HEK293T cells co-expressing BirA-WT (biotin ligase) and AP-WT 1268 
LRRK2 (acceptor peptide) were lysed following a biotin pulse to label dimeric LRRK2, and 1269 
extracts bound to streptavidin-coated ELISA plates. LRRK2 was detected using anti-LRRK2 1270 
conjugated to HRP (clone N241A/B34) and expressed as a ratio of total LRRK2 levels detected 1271 
by ELISA in parallel plates coated with total LRRK2 antibodies (clone c41-2). In the plot, 1272 
WT/WT NP refers to cells expressing WT LRRK2 dimers that were harvested without 1273 
receiving a biotin pulse (no pulse). AdoCbl significantly reduced levels of dimeric WT-1274 
LRRK2. Sub-panel shows representative immunoblot of parallel extracts detected with anti-1275 
LRRK2 (clone N241A/B34). BirA-LRRK2 represents the top band, and AP-LRRK2 the bottom 1276 
band. (e) HEK293T cells expressing BirA- G2019S or I2020T mutant LRRK2 together with AP- 1277 
G2019S or I2020T LRRK2, and dimeric LRRK2 quantified by ELISA. Treatment with AdoCbl 1278 
significantly reduces dimeric mutant LRRK2. * p < 0.05 compared to WT/WT-LRRK2; *** p < 1279 
0.001 compared to G2019S-LRRK2 dimers or I2020T-LRRK2 dimers alone. (f) Representative 1280 
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immunoblot of parallel extracts detected with anti-LRRK2 (clone N241A/B34). BirA-LRRK2 1281 
represents the top band, and AP-LRRK2 the bottom band.   1282 
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Fig. 5. AdoCbl rescues mutant human LRRK2-induced behavioral defects and 1302 
dopaminergic neurodegeneration in C. elegans. (a) AdoCbl dose dependently rescues the loss 1303 
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of basal slowing response in transgenic hLRRK2-G2019S C. elegans. Age-synchronized 1304 
nematodes expressing GFP marker only or additionally hLRRK2-G2019S in dopaminergic 1305 
neurons were treated with either vehicle or AdoCbl in liquid culture during the larval stage L1 to 1306 
L4 (3 days), followed by growth on NGM plates for 3 days prior to behavior assay. Basal 1307 
slowing response was assayed on NGM plates using an unbiased machine-vision analysis system 1308 
(WormLab) as the percent slowing in body bends per 20 s in the presence vs. the absence of 1309 
bacterial lawn. Data represent the mean (± s.d.) of three biological replicates, each with 20-25 1310 
worms per treatment condition. (b) AdoCbl treatment attenuated the loss of dopaminergic 1311 
neurons induced by hLRRK2-G2019S in C. elegans. Representative fluorescence images of 1312 
dopaminergic neurons (CEP neurons within the outlined head region) in transgenic C. elegans 1313 
expressing GFP marker only or additionally hLRRK2-G2019S following treatment with either 1314 
vehicle or 1.25 µM AdoCbl. Age-synchronized nematodes were treated with either vehicle or 1315 
AdoCbl in liquid culture during the larval stage L1 to L4 (3 days), followed by growth on NGM 1316 
plates for 9 days. GFP-tagged dopaminergic neurons in live animals were counted under a 1317 
fluorescence microscope. (c) Quantification of percent dopaminergic neurons survived. Data are 1318 
presented as the mean (± s.d.) of three biological replicates, each with approximately 30-50 1319 
worms per treatment condition. P < 0.01, Students t-test. n.s., not statistically significant.  1320 
 1321 
 1322 
 1323 
Fig. 6. AdoCbl rescues deficits in Drosophila visual physiology induced by the 1324 
dopaminergic expression of human LRRK2-G2019S. (a) Outline of the retinal neural network 1325 
of Drosophila, with three main neuronal layers: photoreceptors, lamina neurons and medulla 1326 
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neurons (Modified after Afsari et al31). (b) Contrast response functions (CRFs) for the 1327 
photoreceptors, lamina neurons and medulla neurons show that the dopaminergic expression of 1328 
hLRRK2-G2019S (DA → G2019S) flies have a much bigger response than either the DA → 1329 
hLRRK2 or the DA → G2019S which have been fed 2.5 µM AdoCbl. (c) Dose-response curve 1330 
for the effect of AdoCbl on the DA → G2019S flies, shows a 50% reduction in phenotypes by 1331 
250-500 nM AdoCbl, with almost complete rescue by 2.5 µM AdoCbl. (d) There is no effect of 1332 
2.5 µM AdoCbl on flies with dopaminergic expression of kinase-dead hLRRK2-G2019S-1333 
K1906M (DA → KD). (e) The visual response of flies with wild-type dLRRK2 is reduced by 1334 
2.5µM AdoCbl. (f) Applying 2.5 µM AdoCbl to dLRRK¯ transheterozygote flies (in which the 1335 
drosophila LRRK2 homolog has been knocked out) has no statistically significant effect. Data 1336 
represents the mean (± s.d.) and the numbers in brackets are the number of flies tested. In (c), 1337 
statistical analysis from Tukey Post-hoc tests on the first principal component of a PCA, which 1338 
accounted for 88% of the variance (Supplementary information, Fig. S9). (d-f), analysis by 1339 
MANOVA.  n.s. not significant; ***p < 0.001). Boxes correspond to the median +/- quartiles. 1340 
Dots indicate data from individual flies. dLRRK¯  genotype: dLRRK^e03680/dLRRK^ex1; wild 1341 
type genotype: w^a/w^1118. 1342 
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 1347 
Fig. 7. AdoCbl prevents LRRK2-G2019S induced neurotoxicity and rescues deficits in 1348 
dopamine transmission in LRRK2-PD mouse models. (a) Quantification of percent apoptotic 1349 
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neurons after LRRK2 overexpression and treatment with MLi-2 or AdoCbl. Cortical neurons 1350 
were co-transfected with LRRK2 and a GFP reporter. Transfected neurons displaying apoptotic 1351 
nuclear morphology were counted 48 h after transfection using DAPI. Apoptotic neurons were 1352 
defined as those having condensed fragmented chromatin comprised of two or more apoptotic 1353 
bodies. Data represents the mean (± s.d.) from n = 3 biological replicates of triplicate coverslips. 1354 
Significance was measured by one-way ANOVA. (b) Quantification of pS1292/Total LRRK2 1355 
after brain slice tissue from LRRK2-G2019S BAC-transgenic mice were treated with AdoCbl. 1356 
One mouse brain provided enough slices to test each treatment condition one time. Three mouse 1357 
brains were used in total, resulting in three biological replicates.  Data are the mean (± s.d.) and 1358 
significance was measured by one-way ANOVA (c) Voltammetric traces of striatal DA release 1359 
evoked at 2-min intervals from G2019S, or (e) R1441G, and WT controls after 2 h treatment 1360 
with control vehicle (water), or with 300 µM AdoCbl. (d) Summary of DA release sustainability 1361 
for G2019S mice (n = 9 sites) or (f) R1441G (n = 10 sites) compared to WT controls. Data are 1362 
expressed as the mean (± s.d.) and were analyzed by two-way ANOVA with Bonferroni’s post 1363 
hoc analysis. For all figures, * p  0.01, ** p  0.001, *** p  0.0001.  1364 







